CN107744145A - 一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法 - Google Patents
一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法 Download PDFInfo
- Publication number
- CN107744145A CN107744145A CN201710910981.7A CN201710910981A CN107744145A CN 107744145 A CN107744145 A CN 107744145A CN 201710910981 A CN201710910981 A CN 201710910981A CN 107744145 A CN107744145 A CN 107744145A
- Authority
- CN
- China
- Prior art keywords
- linolenic acid
- lentinan
- alpha
- microcapsule powder
- wall material
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 title claims abstract description 132
- 235000020661 alpha-linolenic acid Nutrition 0.000 title claims abstract description 67
- 229960004488 linolenic acid Drugs 0.000 title claims abstract description 66
- 229920001491 Lentinan Polymers 0.000 title claims abstract description 65
- 229940115286 lentinan Drugs 0.000 title claims abstract description 65
- 239000003094 microcapsule Substances 0.000 title claims abstract description 44
- 239000000843 powder Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 37
- 239000008346 aqueous phase Substances 0.000 claims abstract description 20
- 239000003381 stabilizer Substances 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000007908 nanoemulsion Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 241000255789 Bombyx mori Species 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 102000004407 Lactalbumin Human genes 0.000 claims description 3
- 108090000942 Lactalbumin Proteins 0.000 claims description 3
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 3
- 241000382353 Pupa Species 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- 235000010489 acacia gum Nutrition 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- 239000005018 casein Substances 0.000 claims description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 3
- 235000021240 caseins Nutrition 0.000 claims description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 3
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 238000005457 optimization Methods 0.000 abstract description 2
- 239000007787 solid Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 8
- 238000004945 emulsification Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
- A23L2/395—Dry compositions in a particular shape or form
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法。所述α‑亚麻酸微胶囊粉由如下质量百分比的原料组成α‑亚麻酸32~37%,水相主壁材28~35%,香菇多糖28~35%,稳定剂1.5~3%。本发明将α‑亚麻酸、香菇多糖与壁材、稳定剂合理配比,并且通过制备方法中各参数的优化获得包埋率、稳定性较优,粒度均匀的微胶囊粉;将α‑亚麻酸、香菇多糖按照特定的百分比含量搭配,优化比例,使两者充分发挥协同作用,使得制得的微胶囊粉起到显著的调节血压的作用。本发明产品制备工艺简单,具有良好的速溶性和稳定性,可应用于固体饮料食品,保证营养物质被人体充分吸收。
Description
技术领域
本发明属于保健品技术领域,更具体地,涉及一种含香菇多糖的α-亚麻酸微胶囊粉及其制备方法。
背景技术
α-亚麻酸(ALA)是有三个双键的多元不饱和脂肪酸(C18H30O2),是一种ω-3必需脂肪酸,是人体必须的营养素之一,对人体的健康有重要的意义。α-亚麻酸制剂也有很多医学上的治疗效果,如提高智力、调节血脂、降血压、抗血栓、抗炎症、保肝等。
香菇多糖具有很明显的抗肿瘤活性,增强宿主对细菌、真菌、病毒和寄生虫感染的抵抗能力,增强自然杀伤细胞和细胞毒性T细胞活性等多种生物学和免疫学活性,是香菇的重要成分之一。香菇多糖也具有调节血压,扩张血管,降低胆管醇,改善血管弹性。
目前还没有涉及含香菇多糖的α-亚麻酸微胶囊粉的报道。
发明内容
针对上述现有技术中的不足,本发明的目的在于一种含香菇多糖的α-亚麻酸微胶囊粉,在拓宽α-亚麻酸应用领域的同时,使得使香菇多糖和α-亚麻酸协同作用,起到调节血压的作用,在食品及保健品领域有较大应用价值。
本发明的另一目的在于提供上述α-亚麻酸微胶囊粉的制备方法。
本发明的上述目的是通过以下技术方案予以实现的。
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸32~37%,水相主壁材28~35%,香菇多糖28~35%,稳定剂1.5~3%。
优选地,所述水相主壁材为乳清蛋白、酪蛋白酸钠、大豆分离蛋白或蚕蛹蛋白粉中的一种或多种。
优选地,所述稳定剂为阿拉伯胶、黄原胶、刺梧桐胶、D-甘露糖醇或海藻酸丙二醇酯中的一种或多种。
优选地,所述α-亚麻酸和香菇多糖的比例为1.1:1。
本发明还提供一种含香菇多糖的α-亚麻酸微胶囊粉的制备方法,包括如下步骤:
S1.将所述水相主壁材按1:2~4比例加水,加热至60~65℃,搅拌20~40min,加入所述稳定剂,继续搅拌20~40min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力30~50MPa;
S3.将所述纳米乳液喷雾干燥,进料温度60~70℃,进风温度160~180℃,出风温度60~75℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
更优选地,所述制备方法包括如下步骤:
S1.将所述水相主壁材按1:2.5比例加水,加热至60~65℃,搅拌30min,加入所述稳定剂,继续搅拌30min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力35~40MPa;
S3.将所述纳米乳液喷雾干燥,进料温度60~70℃,进风温度165~175℃,出风温度65℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
与现有技术相比,本发明有益效果在于:本发明将α-亚麻酸、香菇多糖与壁材、稳定剂合理配比,并且通过制备方法中各参数的优化获得包埋率、稳定性较优,粒度均匀的微胶囊粉;将α-亚麻酸、香菇多糖按照特定的百分比含量搭配,优化比例,使两者充分发挥协同作用,使得制得的微胶囊粉起到显著的调节血压的作用。本发明产品制备工艺简单,具有良好的稳定性,可应用于固体饮料食品,保证营养物质被人体充分吸收。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
以下实施例和对比例中水相主壁材为乳清蛋白、酪蛋白酸钠、大豆分离蛋白或水解蚕蛹蛋白粉中的一种或多种;所述稳定剂为阿拉伯胶、黄原胶、刺梧桐胶、D-甘露糖醇或海藻酸丙二醇酯中的一种或多种。本发明水相主壁材、稳定剂种类在上述物质中选择均为本发明的较优选择,不同物质对本发明微胶囊粉产品的影响差别不大。
以下以具体实施条件为例对本发明方法进行进一步说明。
实施例1
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸35%,水相主壁材30.7%,香菇多糖31.8%,稳定剂2.5%;其中,α-亚麻酸和香菇多糖的比例为1.1:1。
所述含香菇多糖的α-亚麻酸微胶囊粉的制备方法,包括如下步骤:
S1.将所述水相主壁材按1:2.5比例加水,加热至60~65℃,搅拌30min,加入所述稳定剂,继续搅拌30min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力35~40MPa;
S3.将所述纳米乳液喷雾干燥,进料温度60~70℃,进风温度165~175℃,出风温度65℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
实施例2
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸37%,水相主壁材32%,香菇多糖28%,稳定剂3%;其中,α-亚麻酸和香菇多糖的比例为1.3:1。
所述含香菇多糖的α-亚麻酸微胶囊粉的制备方法与实施例1相同。
实施例3
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸32%,水相主壁材31.5%,香菇多糖35%,稳定剂1.5%;其中,α-亚麻酸和香菇多糖的比例为1:1.1。
所述含香菇多糖的α-亚麻酸微胶囊粉的制备方法与实施例1相同。
实施例4
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸37%,水相主壁材28%,香菇多糖32%,稳定剂3%;其中,α-亚麻酸和香菇多糖的比例为1.2:1。
所述含香菇多糖的α-亚麻酸微胶囊粉的制备方法与实施例1相同。
实施例5
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸33%,水相主壁材35%,香菇多糖30%,稳定剂2%;其中,α-亚麻酸和香菇多糖的比例为1.1:1。
所述含香菇多糖的α-亚麻酸微胶囊粉的制备方法与实施例1相同。
实施例6
本实施例所述含香菇多糖的α-亚麻酸微胶囊粉的组分与实施例1相同,不同之处在于制备方法,包括如下步骤:
S1.将所述水相主壁材按1:4比例加水,加热至60~65℃,搅拌40min,加入所述稳定剂,继续搅拌20min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力50MPa;
S3.将所述纳米乳液喷雾干燥,进料温度60~70℃,进风温度180℃,出风温度75℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
对比例1
一种含香菇多糖的α-亚麻酸微胶囊粉,由如下质量百分比的原料组成:α-亚麻酸25%,水相主壁材35%,香菇多糖38%,稳定剂2%。
所述含香菇多糖的α-亚麻酸微胶囊粉的制备方法与实施例1相同。
对比例2
本对比例所述含香菇多糖的α-亚麻酸微胶囊粉的组分与实施例1相同,不同之处在于制备方法,包括如下步骤:
S1.将所述水相主壁材按1:5比例加水,加热至70℃,搅拌50min,加入所述稳定剂,继续搅拌50min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力60MPa;
S3.将所述纳米乳液喷雾干燥,进料温度80℃,进风温度200℃,出风温度85℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
将实施例1~6和对比例1~2制备得到的微胶囊粉进行包埋率测试(测试方法采用现有),结果见下表:
本发明采用微胶囊形式,优化α-亚麻酸和香菇多糖的百分含量,制得的微胶囊包埋率高、粒度均匀,稳定性好。当改变本发明组分和制备方法时,将直接影响微胶囊粉的包埋率和稳定性,经大量实验证实,只有在本发明限定范围内才能获得质量更优的产品。
经急性毒性试验合格后,临床上选取原发性高血压患者100例,无论服用降压药物与否,收缩压≥140mmHg,舒张压≥90mmHg,满足两者中任一项即可纳入。受试者年龄为30~45岁,无孕期及哺乳期女性。
受试者根据随机盲法的要求进行分组,在考虑受试者病程、病情、服药种类、性别、年龄等影响因素的前提下,按受试者的血压水平随机分为5组,每组20例,早晚分别喂服实施例1、3、4和对比例1、2的微胶囊粉,每次2.5mg/kg,共服用1周。
1周后用血压计检测收缩压和舒张压,测量前受试者休息15~20min,测量时间选择在早8:30~9:30。检测结果如下:
经进一步计算,实施例1相较于对比例1~2具有显著性差异(P<0.01)。且本发明实施例调节血压的效果要远好于对比例。
以上详细描述了本发明的实施,但是,本发明并不限于上述实施方式中的具体细节,在本发明的技术构思范围内,可以对本发明的技术方案进行多种简单变型,这些简单变型均属于本发明的保护范围。
Claims (6)
1.一种含香菇多糖的α-亚麻酸微胶囊粉,其特征在于,由如下质量百分比的原料组成:α-亚麻酸32~37%,水相主壁材28~35%,香菇多糖28~35%,稳定剂1.5~3%。
2.根据权利要求1所述的一种含香菇多糖的α-亚麻酸微胶囊粉,其特征在于,所述水相主壁材为乳清蛋白、酪蛋白酸钠、大豆分离蛋白或蚕蛹蛋白粉中的一种或多种。
3.根据权利要求1所述的一种含香菇多糖的α-亚麻酸微胶囊粉,其特征在于,所述稳定剂为阿拉伯胶、黄原胶、刺梧桐胶、D-甘露糖醇或海藻酸丙二醇酯中的一种或多种。
4.根据权利要求1所述的一种含香菇多糖的α-亚麻酸微胶囊粉,其特征在于,所述α-亚麻酸和香菇多糖的比例为1.1:1。
5.权利要求1所述的一种含香菇多糖的α-亚麻酸微胶囊粉的制备方法,其特征在于,包括如下步骤:
S1.将所述水相主壁材按1:2~4比例加水,加热至60~65℃,搅拌20~40min,加入所述稳定剂,继续搅拌20~40min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力30~50MPa;
S3.将所述纳米乳液喷雾干燥,进料温度60~70℃,进风温度160~180℃,出风温度60~75℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
6.根据权利要求4所述制备方法,其特征在于,包括如下步骤:
S1.将所述水相主壁材按1:2.5比例加水,加热至60~65℃,搅拌30min,加入所述稳定剂,继续搅拌30min,制得壁材;
S2.将所述α-亚麻酸、香菇多糖与步骤S1获得的壁材相混合,经高压均质乳化成粒径为100~200nm的纳米乳液,均质压力35~40MPa;
S3.将所述纳米乳液喷雾干燥,进料温度60~70℃,进风温度165~175℃,出风温度65℃,制得所述含香菇多糖的α-亚麻酸微胶囊粉。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710910981.7A CN107744145A (zh) | 2017-09-29 | 2017-09-29 | 一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710910981.7A CN107744145A (zh) | 2017-09-29 | 2017-09-29 | 一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107744145A true CN107744145A (zh) | 2018-03-02 |
Family
ID=61255090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710910981.7A Pending CN107744145A (zh) | 2017-09-29 | 2017-09-29 | 一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107744145A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109497559A (zh) * | 2018-11-16 | 2019-03-22 | 杭州天龙集团有限公司 | 一种富含α-亚麻酸的孕妇食品及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101125133A (zh) * | 2007-09-27 | 2008-02-20 | 武汉麦可得生物技术有限公司 | 一种不饱和脂肪酸微胶囊的制备工艺及应用 |
-
2017
- 2017-09-29 CN CN201710910981.7A patent/CN107744145A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101125133A (zh) * | 2007-09-27 | 2008-02-20 | 武汉麦可得生物技术有限公司 | 一种不饱和脂肪酸微胶囊的制备工艺及应用 |
Non-Patent Citations (3)
Title |
---|
刘修树等: "《天然药物化学》", 28 February 2017, 华中科技大学出版社 * |
张美莲: "香菇多糖微球的制备工艺研究", 《海峡药学》 * |
白鸿: "《保健食品功效成分检测方法》", 31 May 2011, 中国中医药出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109497559A (zh) * | 2018-11-16 | 2019-03-22 | 杭州天龙集团有限公司 | 一种富含α-亚麻酸的孕妇食品及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106689964B (zh) | 一种杀菌型发酵蛋白饮料用稳定剂、杀菌型发酵蛋白饮料剂及制备方法 | |
CN108936687A (zh) | 一种补充维生素kd钙的软胶囊及其制备方法 | |
CN109329949A (zh) | 包含hmb钙和乳清蛋白的全营养混悬液及制备方法 | |
CN105455133A (zh) | 一种预消化型全营养液及其制备方法 | |
CN105434331B (zh) | 一种自乳化辅酶q10油剂及其制备方法和应用 | |
TW200812502A (en) | Stabiliser system for liquid nutritional compositions | |
CN108094549A (zh) | 一种功能型液态乳及其制备方法 | |
CN108902593A (zh) | 一种苦荞麦澄清饮料及其制备方法 | |
CN104768383B (zh) | 用于制备具有减少的消化凝结的含蛋白质和脂质的组合物的方法 | |
CN107744145A (zh) | 一种含香菇多糖的α‑亚麻酸微胶囊粉及其制备方法 | |
CN108567937A (zh) | 一种补钙软胶囊及其制备方法 | |
CN101167793A (zh) | 核桃油脂肪乳剂及其制造方法 | |
CN110898027A (zh) | 促进血钙入骨的维生素k2(mk-7)软胶囊及制备方法 | |
CN108159084B (zh) | 一种具有降血脂作用的粪肠球菌和菊粉复合物及其制法 | |
CN107736611A (zh) | 一种含香菇多糖的dha微胶囊粉及其制备方法 | |
CN107114491A (zh) | 老年人茶油及其生产方法 | |
JPS60203172A (ja) | 経口・経管栄養食 | |
CN108041549A (zh) | 一种富含鲜味肽营养鸡汤的制备方法及其在制备抗疲劳产品中的应用 | |
CN108902986A (zh) | 一种补充维生素ad的软胶囊及其制备方法 | |
CN108576234A (zh) | 提高产妇泌乳量的食品及其制备方法 | |
CN107320468A (zh) | 复合磷脂脂质体口服液及其制备方法和应用 | |
JP3177612B2 (ja) | 発酵・水解動物肝臓抽出物の製造方法、発酵・水解動物肝臓抽出物、及びそれを含有してなる製剤 | |
CN106617103A (zh) | 一种含丝肽素的保健软胶囊及其制备方法 | |
TWI660732B (zh) | 綠豆發酵萃取物用於製備促進傷口癒合的醫藥品的用途 | |
CN105395574A (zh) | 一种药食两用防治心脑血管病复方角鲨烯鱼油软胶囊 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180302 |